Kaisha Pharma, promoted by the Dadachanji Group, has been launched with an initial investment of Rs. 4050 Million (€45 million) as the group returns to the pharmaceutical glass-packaging segment after exiting Schott Kaisha in 2021. The company will manufacture primary pharmaceutical packaging products including ampoules, vials, prefilled syringes and cartridges, along with ready-to-use (RTU) platforms for vials, syringes and cartridges, and is also developing specialty containment solutions for biologics, advanced therapeutics and sensitive drug formulations. The new venture is setting up a manufacturing complex spread over more than 300,000 square feet, equipped with integrated production lines, camera-based inspection systems, and analytical and testing laboratories. The Rs. 4050 Million initial deployment forms part of a larger multi-million-euro investment commitment towards expanding infrastructure, manufacturing capacity and operational capabilities. The promoters bring over 35 years of experience in pharmaceutical glass packaging, having earlier built one of India's largest tubular glass packaging companies. Given the nature of the project, key equipment and machinery typically required would include glass-forming and tubing machines, ampoule and vial forming lines, automated inspection and camera-based defect detection systems, sterilization and washing lines, prefilled syringe assembly lines, cartridge forming equipment, and analytical/quality testing laboratory instruments.